Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Fennec Pharmaceuticals (FRX) Stock Price & Analysis

41 Followers

FRX Stock Chart & Stats

CA$16.56CA$0.51(3.18%)
At close: 4:00 PM EST
C$15C$17.5Aug 19Sep 3Sep 15Sep 28Oct 13Oct 26Nov 12
Day’s Range
CAD 15.65 - CAD 16.94
52-Week Range
CAD 7.59 - CAD 18.50
Previous Close
CAD 16.05
Volume
N/A
Average Volume (3M)
399
Market Cap
CAD 585.48M
Enterprise Value
CAD 356.83M
Total Cash (Recent Filing)
CAD 48.68M
Total Debt (Recent Filing)
CAD 0
Price to Earnings (P/E)
507.4
Beta
1.91
Next Earnings
Mar 30, 2027 (Est.)
EPS Estimate
0.21
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Sustained PEDMARK Commercial Growth

PEDMARK is demonstrating sustained commercial adoption, with strong year-over-year growth and eight consecutive quarters of expansion. Continued demand across academic and community oncology accounts, combined with broader commercial reach, supports a durable revenue-growth runway over the next several quarters.

High-margin, Improving Profitability And Cash Generation

The product has highly attractive gross economics, and recent revenue growth is translating into positive earnings and cash generation. Record quarterly EBITDA and operating cash flow indicate meaningful operating leverage, strengthening Fennec’s ability to fund commercial expansion internally.

Debt-free Balance Sheet

A debt-free balance sheet and substantial cash position reduce financial risk and preserve flexibility for evidence generation, commercial investment, or strategic opportunities. This stronger capital structure gives Fennec greater capacity to absorb execution variability while supporting continued PEDMARK growth.

Bears Say

Profitability And Cash-flow Durability Remain Inconsistent

Although recent results are positive, the historical pattern shows that earnings and cash generation have not yet been consistently durable. Periods of losses and deeply negative cash flow make future results more sensitive to commercialization pace, cost control, and the timing of patient conversions.

Higher Commercial Investment Pressures Operating Expenses

Fennec is investing heavily to expand its sales organization and market awareness, which can support long-term adoption but weighs on near-term operating leverage. If incremental territories take longer to mature, higher fixed and commercial costs could delay sustained margin expansion.

Revenue Conversion And Market Expansion Timing Uncertainty

The growth opportunity depends on converting enrollments, formulary access, and clinical evidence into completed infusions and reimbursed sales. Variable timing can make revenue less predictable, while uncertain adult guideline adoption and a lengthy Japan market-access process may defer additional growth.

Fennec Pharmaceuticals News

FRX FAQ

What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was C$7.59 and its highest was C$18.50 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Fennec Pharmaceuticals’s market cap is C$585.48M.
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s next earnings report is estimated for Mar 30, 2027 (not yet confirmed), which is in 135 days.
How were Fennec Pharmaceuticals’s earnings last quarter?
Fennec Pharmaceuticals released its earnings results on Nov 12, 2026. The company reported C$0.171 earnings per share for the quarter, beating the consensus estimate of C$0.137 by C$0.034.
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is 0.21.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 35,305,120 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Fennec Pharmaceuticals reported an EPS of C$0.171 in its last earnings report, beating expectations of C$0.137. Following the earnings report the stock price went up 20.767%.
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:FRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology